treatment
treatment on World Data Ocean: a running collection of 2 stories we have gathered and hand-picked because they are worth your time. Every post here touches on treatment in some way — the news, the analysis, the deep dives, and the occasional surprise find. A Global Hub for Ocean Intelligence 4 World Data Ocean is a centralized digital platform where researchers, scientists, and ocean enthusiasts converge to explore, analyze, and… New stories are added to this page as we find them, so check back if you want to keep up with what is happening around treatment, or subscribe to the RSS feed to get them as soon as they are published. Browse the collection below, or head back to the homepage to see everything World Data Ocean is covering right now.
An unproven autism drug got a boost after a White House briefing
In fall 2025, the Trump administration’s endorsement of leucovorin as an autism therapy sparked a significant increase in its prescription for children, despite a lack of newly validated evidence supporting its efficacy. This event underscores the potential impact of policy pronouncements on medical practices and public health. Our reporting emphasizes the critical need for empirical data to guide treatment decisions. For related advancements in medical innovation, see our article, "No refrigerator, no problem. This experimental vaccine doesn’t need it."
Newborn screening for cancer risk could save lives. Should it be done?
Emerging genetic screening technologies now offer the potential to identify cancer-linked mutations in newborns, presenting a paradigm shift in preventative healthcare. This longitudinal approach, while promising earlier intervention and improved patient outcomes, necessitates careful consideration of ethical and practical implications. Validated screening protocols could empower proactive management strategies, but concerns regarding psychological impact and potential for false positives require rigorous empirical evaluation before widespread implementation. The debate surrounding newborn cancer risk screening demands a balanced assessment of benefits and risks.